Association of Free Thyroxine with Progression-Free Survival in Intermediate and High Risk Differentiated Thyroid Cancer

甲状腺癌 游离甲状腺素 肿瘤科 内科学 癌症 医学 联想(心理学) 甲状腺 内分泌学 心理学 甲状腺功能 心理治疗师
作者
Raisa Ghosh,Sungyoung Auh,Sriram Gubbi,Padmasree Veeraraghavan,Craig Cochran,Leila Shobab,Mark L. Urken,Kenneth D. Burman,Leonard Wartofsky,Joanna Kłubo-Gwieździńska
出处
期刊:The Journal of Clinical Endocrinology and Metabolism [Oxford University Press]
被引量:1
标识
DOI:10.1210/clinem/dgae537
摘要

Abstract Context Supraphysiologic T4 doses are used in intermediate- and high-risk patients with differentiated thyroid cancer (IR/HR-DTC) to suppress tumor progression by TSH. However, preclinical data suggest that T4 can also act as a growth stimulus for cancer, but there is no clinical evidence supporting this claim. Objective We analyzed the association between free T4 (FT4) and progression-free survival (PFS) in patients with IR/HR-DTC. Methods This longitudinal cohort study, approved by multi-institutional review board, included patients with IR/HR-DTC treated uniformly with total thyroidectomy, radioiodine, and TSH suppression therapy, with at least 3 TSH and FT4 values available. Association between FT4 and PFS at landmarks 6, 12, and 18 months was assessed by Kaplan-Meier survival curves, whereas competing risks were assessed through Cox proportional hazards model. Results From 739 screened patients, 382 met the inclusion criteria and were characterized by a median age of 46 (34-59) years, 64.1% women, and treated with a median radioiodine dosage of 159 (110-410) mCi. During follow up of 7.1 (3.4-12.7) years, 34.6% experienced disease progression. Elevated FT4, observed in 29.3% of patients, was not associated with worse PFS (hazard ratio [HR], 0.9; CI, 0.54-1.5; P = .69), whereas age (HR, 1.02; CI, 1.004-1.04; P = .01), tumor size (HR, 1.15; CI, 1.04-1.28; P = .01) and metastases to the lateral neck lymph nodes (HR, 2.9; CI, 1.7-4.74; P < .001), bones (HR, 4.87; CI, 1.79-13.3; P = .002), and brain (HR, 5.56; CI; 2.54-12.2; P < .001) were associated with shorter PFS. Conclusion Contrary to preclinical evidence, elevated FT4 levels do not affect PFS in patients with IR/HR-DTC.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
132完成签到,获得积分20
刚刚
ruby发布了新的文献求助10
刚刚
朝乾夕惕完成签到,获得积分10
1秒前
1秒前
1秒前
强健的书竹完成签到,获得积分10
2秒前
梅心发布了新的文献求助10
2秒前
2秒前
laohanyin完成签到,获得积分10
2秒前
Akim的应助被共产主义战士采纳,获得10
3秒前
3秒前
清淮发布了新的文献求助10
3秒前
柏舟完成签到,获得积分10
3秒前
3秒前
4秒前
meshia完成签到,获得积分10
4秒前
悦耳初晴的应助被霸气秀采纳,获得10
5秒前
ccccccp发布了新的文献求助10
5秒前
6秒前
甘峰发布了新的文献求助10
6秒前
6秒前
悦耳初晴的应助被高胖采纳,获得10
6秒前
hhhh08完成签到,获得积分10
7秒前
zhangyuqi完成签到,获得积分10
8秒前
斯坦森完成签到,获得积分10
8秒前
Richard完成签到,获得积分10
9秒前
coolru发布了新的文献求助400
9秒前
a15670270171发布了新的文献求助10
9秒前
情怀的应助被果冻采纳,获得10
9秒前
科研通AI6.2的应助被papercomecome采纳,获得10
9秒前
靳子劼发布了新的文献求助10
10秒前
20251107130112关注了科研通微信公众号
10秒前
lianxin完成签到 ,获得积分10
10秒前
超级大馒头完成签到,获得积分10
10秒前
xzj发布了新的文献求助10
10秒前
嘻嘻嘻发布了新的文献求助10
10秒前
伶俐云朵完成签到,获得积分10
10秒前
11秒前
舒服的远望完成签到,获得积分10
12秒前
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8154126
求助须知:如何正确求助?哪些是违规求助? 9550679
关于积分的说明 21700229
捐赠科研通 7743193
什么是DOI,文献DOI怎么找? 3425640
关于科研通互助平台的介绍 2550854
邀请新用户注册赠送积分活动 2469329